Abcellera Biologics Inc. Stock Price, News & Analysis

AbCellera (Nasdaq: ABCL) unveiled data on its innovative T cell engager platform at the AACR 2022 Annual Meeting. The research showcases a diverse range of CD3-binding antibodies for developing bispecific T cell engagers aimed at enhancing cancer therapies. Bo Barnhart, VP of Translational Research, emphasized the potential of these new antibodies to boost the efficacy of oncology treatments. The platform combines rapid screening capabilities with favorable developability properties, reducing engineering risks and enhancing the probability of successful cancer drug development.

AbCellera (Nasdaq: ABCL) reported a total revenue of $375 million for 2021, a 61% increase from $233 million in 2020. The company ended the year with liquidity exceeding $720 million. Key achievements included 26 new program starts, totaling 78 cumulative starts. Net earnings rose to $153 million ($0.56 per share), up from $119 million ($0.53 per share) in 2020. R&D expenses increased to $62 million, reflecting investment in the company's platform. AbCellera also expanded its partner network significantly, increasing programs under contract to 156.

AbCellera (Nasdaq: ABCL) announced its participation in the Truist Securities AI Symposium on March 1, 2022, at 8:20 a.m. Pacific Time. The panel, titled “Integrated Platforms for AI-based Drug Discovery,” will feature executives from the Company discussing groundbreaking advancements in drug development. Interested parties can access a live audio webcast through AbCellera's Investor Relations website, with a replay available afterwards. AbCellera specializes in antibody discovery, partnering with various drug developers to expedite the development process for new treatments.

AbCellera (Nasdaq: ABCL) will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 12:40 p.m. PT. Investors and interested parties can access the live audio webcast on AbCellera's Investor Relations website, with a replay available afterward. AbCellera is a tech company specializing in analyzing immune systems to discover antibodies for drug development, partnering with pharmaceutical and biotechnology firms to streamline processes and address challenges in drug development.

AbCellera (Nasdaq: ABCL) has received Emergency Use Authorization (EUA) from the U.S. FDA for bebtelovimab (LY-CoV1404), its antibody treatment for mild-to-moderate COVID-19 in high-risk patients. Bebtelovimab effectively neutralizes the Omicron variant, including BA.2, demonstrating broad efficacy against circulating SARS-CoV-2 variants. The authorized dosage is 175 mg as an intravenous injection. Additionally, Lilly has contracted to supply up to 600,000 doses to the U.S. government by March 31, 2022, and an option for 500,000 more by July 31, 2022.

AbCellera (Nasdaq: ABCL) has announced a purchase agreement with Eli Lilly for the supply of up to 600,000 doses of the investigational drug bebtelovimab. The deal is valued at a minimum of $720 million and is contingent upon obtaining Emergency Use Authorization from the FDA. Testing confirms that bebtelovimab neutralizes the Omicron variant and its subvariants. This drug is part of AbCellera's rapid response to COVID-19, initiated in 2020, which also led to the development of bamlanivimab.

AbCellera (Nasdaq: ABCL) will report its full year 2021 financial results on February 24, 2022, after market close. The earnings conference call will commence at 2:00 p.m. PT (5:00 p.m. ET), with a live webcast available on AbCellera’s Investor Relations website. The company specializes in antibody development, partnering with various drug developers to enhance drug development efficiency.

AbCellera (Nasdaq: ABCL) announced changes in its Board of Directors, appointing Andrew W. Lo, Ph.D., as an independent director, while John Hamer, Ph.D., resigned. Dr. Lo, known for his innovative financial engineering and machine learning in drug development, will join the Audit and Compensation Committees. CEO Carl Hansen praised Dr. Lo's expertise in connecting financial structures with biomedical innovation. Hamer, who served since 2018, was acknowledged for his valuable contributions. These changes aim to enhance AbCellera's strategic direction in antibody therapy development.

AbCellera (Nasdaq: ABCL) announced an expanded Emergency Use Authorization (EUA) from the FDA for the combination of bamlanivimab and etesevimab for pediatric patients under 12, including neonates. The EUA permits treatment for mild to moderate COVID-19 and post-exposure prophylaxis. Data from the BLAZE-1 Phase 2/3 clinical trial indicated a median symptom resolution of 7 days. The treatment shows efficacy against the Delta variant, currently prevalent in the U.S.